Skip to content

Carbohydrate Oxidation in Elite Wheelchair Racers During Marathon Simulation

Carbohydrate Oxidation in Elite Wheelchair Racers During Marathon Simulation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04145050
Acronym
COW
Enrollment
12
Registered
2019-10-30
Start date
2022-12-01
Completion date
2024-07-01
Last updated
2021-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dietary Carbohydrate, Para-Athletes

Brief summary

To examine the effect of varying amounts of carbohydrate ingestion on performance, gastrointestinal experiences, and other physiological markers in elite wheelchair racers during a simulated marathon.

Detailed description

The metabolic demands created by endurance activities, which include muscle and liver glycogen depletion as well as losses in body fluids and electrolytes, are significant limitations to the performance potential of the athlete. For this reason, a well-supported recommendation exists for such athletes to consume a carbohydrate (CHO) formula, in particular, one containing electrolytes during their activity. Furthermore, the current CHO recommendations to support prolonged activity have been developed specifically for able-bodied athletes, thus are potentially inappropriate for para athletes. Metabolic and physiological functions are altered in individuals with physical disabilities, so it is unknown how transferable these recommendations are to para athletes. As such, it is important to understand this population's unique carbohydrate requirements for performance optimization. Recently, our group showed stable elevated circulating glucose concentrations by utilizing two different sources of CHO dosed at 60 g/h when compared to water. Significantly improved performance was observed with both CHO conditions. These findings, combined with studies showing decreased net muscle glycogen degradation during intravenous glucose infusion (3.5 g/min), show the importance of plasma glucose concentration for sustained performance. Therefore, the purpose of this study is to investigate the SCI-specific responses to exogenous CHO during a full marathon simulation (MS). Twelve highly trained men and women (20-50 yrs old) will be recruited to the study. The inclusion criteria are: 1.) Best marathon time lower than 2h 2.) and ≥6 months of prior training history. After initial screenings, participants will perform three marathon (MS) trials. In cross-over trials, each subject will participate in a MS trial consisting of a challenge (90% of subject's best marathon time) followed by a time trial (TT) representing the last 10% of the marathon time. During each MS trial, participants will be randomly assigned to receive either water, 30g, or 60g of carbohydrate (CHO) every 15 minutes in the form of a sports nutrition beverage. Repeated blood and breath sampling will occur throughout the MS. These samples will be used to determine glucose concentration, lactate concentration, as well as CHO and fat oxidation. Heart rate, core temperature, blood pressure, ratings of perceived exertion and GI symptoms will also be assessed throughout the MS and after the time trial. Completion of this research study will help to identify more appropriate CHO recommendations for para athletes to support prolonged endurance exercise. This will aid in the understanding of the unique physiological and metabolic needs of para athletes as compared to their able-bodied counterparts, thus enhancing inclusivity within sports nutrition literature.

Interventions

OTHERCarbohydrate dosing

The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.

Sponsors

University of Illinois at Urbana-Champaign
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

Participants as well as researchers will not be informed of trial intervention

Intervention model description

Randomized, Cross-Over

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* \< 2-hour best marathon time * 6 months prior training history

Exclusion criteria

* \- Chronic Smoking or tobacco use * Active cardiovascular disease * Diabetes Mellitus or other metabolic disorders * Liver kidney, or urinary disease * Musculoskeletal/Orthopedic disorders (e.g., osteoarthritis, rheumatoid arthritis, tendinitis, gout, fibromyalgia, patellar tendinopathy, or chronic low back pain) * Neuromuscular disorders * hypertension * Diagnosed GI tract diseases * Heart Disease * Neurological disease * Epilepsy * Respiratory disease * Pregnancy * Contraindications for exercise * \<6 months of prior training history

Design outcomes

Primary

MeasureTime frameDescription
Performance10-15 minutesPerformance will be measured by time required to complete a 2.6 mile time-trial immediately following marathon simulation

Secondary

MeasureTime frameDescription
Ratings of gastrointestinal (GI) experiencesThroughout experimental protocol for 1.5 - 2 hoursUsing a visual analog scale (Visual Analog Symptom Scale), participants will record GI symptoms (from 0-100 whereby higher numbers indicate worse experiences) at various time points throughout experimental trial
Blood Glucose ConcentrationThroughout experimental protocol for 1.5 - 2 hoursBlood glucose concentration will be measured at various time points throughout experimental trial
Blood Lactate ConcentrationThroughout experimental protocol for 1.5 - 2 hoursBlood lactate concentration will be measured at various time points throughout experimental trials
Core TemperatureThroughout experimental protocol for 1.5 - 2 hoursCore temperature will be measured at various time points throughout experimental trials via ingestible thermometer sensors
Rated Perceived Exertion (RPE)Throughout experimental protocol for 1.5 - 2 hoursRPE, or how hard an athlete feels they are working, will be recorded at various time points throughout the experimental trial

Countries

United States

Contacts

Primary ContactSusannah E Scaroni, B.S.
scaroni1@illinois.edu509-280-3743
Backup ContactAmadeo F Salvador, M.S.
amadeos2@illinois.edu

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026